New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases

AIMS: Therapeutic drug monitoring (TDM) of infliximab (IFX) appears to be beneficial for patients with inflammatory bowel disease (IBD). However, the recommended target concentrations depend partly on the method used to quantify IFX. Since we recently developed a liquid chromatography–tandem mass sp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Nemoz, Benjamin, Ternant, David, Bailly, Sébastien, Gautier‐Veyret, Elodie, Jourdil, Jean‐François, Bonaz, Bruno, Stanke‐Labesque, Françoise
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422646/
https://ncbi.nlm.nih.gov/pubmed/30575085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13845
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller